Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
June 8, 2009
- Kenko.com, Wellnet Sue Korosho Claiming that Ministerial Ordinance Goes against Law
June 8, 2009
- Initiate Policies that Attract R&D: PhRMA Chairman D. Brennan
June 8, 2009
- Schedule for Medical Materials System Reform Approved
June 8, 2009
- Ryukaikon Reviews One Year of Efforts to Improve Distribution Business Practices
June 8, 2009
- Encouraging Results Obtained with Lurasidone in PIII Trial: DSP
June 8, 2009
- Otsuka: Hyponatremia Drug Approved in the US
June 8, 2009
- R&D NEWS IN BRIEF
June 8, 2009
- Chuikyo Subcommittee to Review Whether Price Gaps Promote Use of Generics
June 8, 2009
- Sleep Disorders Increase Risk of Other Diseases
June 8, 2009
- Sawai: Sales, Profits Up Driven by Gov't Policy to Promote Use of Generics
June 8, 2009
- Only 20% of Mothers Talk to Daughters about GYN Diseases
June 8, 2009
- Publicity on RLS Essential for Patients, Physicians
June 8, 2009
- Toho: Operating Profit Rate Down to 0.36%
June 1, 2009
- Asahi Kasei Pharma: License Fee for Famvir Boost Sales 13.1%
June 1, 2009
- Overseas Sales of Top-Eight Companies Up to 43.1% of Total Sales
June 1, 2009
- Yakult Honsha: Elplat Props Up Business
June 1, 2009
- Taisho: Sales Up 2.6% with Addition of Biofermin
June 1, 2009
- SymBio Licenses Bendamustine to Eisai in South Korea, Singapore
June 1, 2009
- Kyorin: Sales Up 12.1% Driven by Kipres, Pentasa
June 1, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…